Pentixapharm Holding (DB:PTP) - Stock Price, News & Analysis

PTP Stock Overview

Operates as a clinical-stage radiopharmaceutical development company.

PTP fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Risk Analysis

Has not reported any financial data

Shares are highly illiquid

Does not have a meaningful market cap (€86M)

Pentixapharm Holding AG Competitors

Paul Hartmann

DB:PHH2

€777.8m

PULSION Medical Systems

MUN:PUS

€132.7m

LIMES Schlosskliniken

XTRA:LIK

€105.5m

MEDICLIN

XTRA:MED

€115.9m

Price History & Performance

Summary of all time highs, changes and price drops for Pentixapharm Holding
Historical stock prices
Current Share Price	€3.40
52 Week High	€5.10
52 Week Low	€3.36
Beta	0
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-24.44%

Recent updates

Shareholder Returns

	PTP	DE Medical Equipment	DE Market
7D	-4.8%	-0.3%	0.4%
1Y	n/a	6.1%	14.9%

Return vs Industry: Insufficient data to determine how PTP performed against the German Medical Equipment industry.

Return vs Market: Insufficient data to determine how PTP performed against the German Market.

Price Volatility

Is PTP's price volatile compared to industry and market?
PTP volatility
PTP Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.1%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: PTP's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine PTP's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2019	n/a	Hakim Bouterfa	www.pentixapharm.com

Pentixapharm Holding AG operates as a clinical-stage radiopharmaceutical development company. It focuses on developing CXCR4 ligand-based radiopharmaceutical approaches for diagnostic and therapeutic programs in various hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases. The company’s clinical pipeline includes PentixaTher, an Yttrium-90-based therapeutic against non-Hodgkin lymphomas; and PentixaFor, a Gallium-68-based companion diagnostic.

Pentixapharm Holding AG Fundamentals Summary

How do Pentixapharm Holding's earnings and revenue compare to its market cap?
PTP fundamental statistics
Market cap	€85.67m
Earnings (TTM)	€0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is PTP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PTP income statement (TTM)
Revenue	€0
Cost of Revenue	€0
Gross Profit	€0
Other Expenses	€0
Earnings	€0

Last Reported Earnings

n/a

Next Earnings Date

Nov 12, 2024

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did PTP perform over the long term?

See historical performance and comparison

Pentixapharm Holding DB:PTP Stock Report